Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Deferred Taxes: 2023-2025

Historic Deferred Taxes for Gyre Therapeutics (GYRE) over the last 3 years, with Sep 2025 value amounting to -$531,000.

  • Gyre Therapeutics' Deferred Taxes was N/A to -$531,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year change of. This contributed to the annual value of -$1.0 million for FY2024, which is 13.62% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Deferred Taxes stood at -$531,000, which was down 77.00% from -$300,000 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Deferred Taxes high stood at -$97,000 for Q2 2024, and its period low was -$592,000 during Q4 2024.
  • Moreover, its 3-year median value for Deferred Taxes was -$306,500 (2024), whereas its average is -$318,400.
  • Its Deferred Taxes has fluctuated over the past 5 years, first soared by 57.83% in 2024, then plummeted by 209.28% in 2025.
  • Quarterly analysis of 3 years shows Gyre Therapeutics' Deferred Taxes stood at -$403,000 in 2023, then crashed by 46.90% to -$592,000 in 2024, then tumbled by 209.28% to -$531,000 in 2025.
  • Its Deferred Taxes was -$531,000 in Q3 2025, compared to -$300,000 in Q2 2025 and -$191,000 in Q1 2025.